卡多尼利马布加化疗作为持续性,复发性或转移性宫癌的第一线治疗方法:成本效益分析
Zuojuan Xiang1, Zhengxiong Li2, Xiaojuan Chen1
1Department of Pharmacy, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Hunan Cancer Hospital, Changsha, China.
Frontiers in immunology
|April 18, 2025
概括
对于中国大多数持久性,复发性或转移性子宫癌 (p/r/mCC) 患者来说,卡多尼利马布加化学疗法不具有成本效益. 然而,它为那些无法接受贝瓦齐祖马布治疗的患者提供了具有成本效益的选择.
科学领域:
- 在瘤学瘤学.
- 卫生经济学 卫生经济学
- 临床试验 临床试验
背景情况:
- 宫癌 (CC) 治疗中的免疫疗法进展在PD-L1-阴性患者中显示出局限性.
- 卡多尼利马布是一种新型双特异性抗体 (抗PD-1/CTLA-4),在COMPASSION-16试验中证明了对p/r/m CC的有效性.
- 这项研究的重点是评估卡多尼利马布在中国医疗保健系统中的成本效益.
研究的目的:
- 评估卡多尼利马布加化学疗法与单独化学疗法的成本效益,用于中国p/r/m CC的第一线治疗.
- 确定卡多尼利马布的经济价值,特别是对于PD-L1阴性患者.
- 分析增量成本效益比率 (ICER),净货币收益 (NMB) 和净健康收益 (NHB).
主要方法:
- 基于COMPASSION-16试验数据开发了一个分区生存模型.
- 该模型使用了3周的周期长度和10年的时间地平线.
- 进行了敏感性,场景和子组分析,以评估模型的稳定性和确定特定的患者群体.
主要成果:
- 卡多尼利马布加化疗的ICER值为70,220.88美元/QALY,超过了支付意愿的门.
- 该疗法对于一般的p/r/m CC人群来说是不具有成本效益的,INMB和INHB的负值.
- 在未接受贝瓦西祖马布治疗的小组患者中观察到成本效益.
结论:
- 卡多尼利马布加化学疗法不是一个成本效益的第一线治疗,一般的p/r/m CC人口在中国.
- 它为那些无法接受贝瓦齐祖马布治疗的患者提供了具有成本效益的替代方案.
- 在子组分析中,经济结果与PD-L1表达水平没有显著的相关性.
更多相关视频
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.4K
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
10.8K
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:21Cancer Survival Analysis
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...